Does diastolic dysfunction precede systolic dysfunction in trastuzumab-induced cardiotoxicity? Assessment with multigated radionuclide angiography (MUGA)

BACKGROUND: Trastuzumab is successfully used for the treatment of HER2-positive breast cancer. Because of its association with cardiotoxicity, LVEF is monitored by MUGA, though this is a relatively late measure of cardiac function. Diastolic dysfunction (DD) is believed to be an early predictor of c...

Full description

Saved in:

Bibliographic Details
Published in:	J Nucl Cardiol
Main Authors:	Reuvekamp, E. J., Bulten, B. F., Nieuwenhuis, A. A., Meekes, M. R. A., de Haan, A. F. J., Tol, J., Maas, A. H. E. M., Elias-Smale, S. E., de Geus-Oei, L. F.
Format:	Artigo
Language:	Inglês
Published:	Springer US 2015
Subjects:	Original Article
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC4956716/ https://ncbi.nlm.nih.gov/pubmed/26048264 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12350-015-0164-x
Tags:	Add Tag No Tags, Be the first to tag this record!

Does diastolic dysfunction precede systolic dysfunction in trastuzumab-induced cardiotoxicity? Assessment with multigated radionuclide angiography (MUGA)

Similar Items